-
DIANA LI
Partner·Shanghai
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
Ms. Li specializes in M&A, private equity, foreign direct investment and general corporate matters. Ms. Li is dedicated to providing services to pharmaceutical, bioscience and other healthcare industry clients.
Education
Shanghai International Studies University, School of Law, LL.B., China
Northwestern University School of Law, LL.M, USA
Professional Qualification
Admitted to practice in the PRC
Admitted to practice in New York
Professional Background
Before joining the firm in 2007, Ms. Li worked at a leading international law firm and a top Chinese law firm for about five years.
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Represented AstraZeneca in its granting exclusive commercialization rights for certain diabetes drugs in the China market to 3SBio for an upfront fee of USD 100 million and for continuous future profits
- Represented AstraZeneca in the arrangements with Aspen in China following the global grant of commercialization rights for anesthesia products to Aspen
- Represented Bayer AG in its acquisition of 100% equity interest in Dihon Pharmaceutical Group, a leading OTC and TCM maker in the China market. (CBLJ Deal of the Year 2015)
- Represented Bayer AG in its internal restructuring of its PRC subsidiaries and in its post-acquisition integration matters after acquiring Merck's OTC business
- Represented TPG in its acquisitions of contract research organizations in Asia
- Represented PAG in its proposed acquisition of 100% equity interest in a domestic pharmaceutical company
- Represented Olympus Capital in its proposed acquisition of a domestic hospital group
- Represented several US biopharma companies in handling clinical trial applications and in establishing new R&D and manufacturing entities in China
- Represented a US medical device manufacturer in granting exclusive commercialization rights for several medical devices to a PRC company
- Represented several international medical device groups, bioscience groups and pharmaceutical companies, including Bayer, Mylan, Fresenius, Baxter, Novartis and Thermo Fisher, in their corporate legal matters, especially regarding market authorization, distribution and sales models as well as structural adjustments in response to developments in PRC law
- Represented Yunfeng Capital and Cainiao in their respective strategic investments in the logistics sector, including in Haier Group, Yuantong Express, Best Logistics and other logistics and express delivery companies
- Represented Warburg Pincus in its investment in Zhongtong Express
- Represented Sequoia Capital in its investment in Pinduoduo, a leading e-commerce platform on WeChat
- Represented Goldman Sachs PIA in its equity investment in Zhejiang Yangfan, a leading private-owned shipbuilding company in China
- Represented Wipro Unza in its acquisition of a domestic cosmetics manufacturer in China
- Represented a variety of leading domestic and international private equity investors, including Goldman Sachs, Carlyle, Guo Sheng, YF Capital, and CCMP, in their investments in China-based portfolio companies in various industries
- Advised Inner Mongolia Yili Group on its acquisition of Oceania Dairy Ltd. in New Zealand
- Advised two leading state-owned enterprises in Shanghai on their proposed joint investment into a dairy group in Britain
- Represented Wuxi Biologics in its listing on the main board of the HKEx
- Represented iKang Group investors in the group's delisting from the NASDAQ and privatization
- Acted as PRC counsel for the underwriters in iKang Group's NASDAQ IPO
